The REPROCELL group has signed a non-exclusive distributorship agreement with A.N.H. Scientific Marketing Co. Ltd. to distribute REPROCELL’s products and services in Thailand.
Maryland, September 2019: The Maryland based REPROCELL Inc. subsidiary, REPROCELL USA Inc. announces that they have received a $292,580 grant from the Maryland Stem Cell Research Fund (MSCRF).
Yokohama, Japan, & San Carlos, California, USA — REPROCELL, Inc., and NeuCyte, Inc., today announced a new distributorship.
Although NeuCyte has direct sales in North America, this new distributorship will grant REPROCELL customers access to NeuCyte's pure and ready-to-use iPSC-derived glutamatergic and GABAergic induced neurons (iNs), supplied with astroglia, media and supplements. These components come in kit formats so the user can set up well-defined, highly functional in vitro co-culture systems for compound screening, disease modeling and neurotoxicity assessment.
The lab-scale system will allow researchers to study and culture stem cells in suspension
Glasgow, UK: REPROCELL Europe Ltd today announced exclusive distribution rights to a single-use reactor series for stem cell culture in 11 European countries*. The ABLE Biott Bioreactor System is a lab-scaled bioreactor that offers a new way for stem cell researchers to study and culture pluripotent stem cells.
“We are excited to offer our customers the chance to access this innovative new bioreactor, which is ideal for the culture of pluripotent stem cells” said Dr David Bunton, CEO at REPROCELL Europe Ltd. “The product has been rapidly and widely adopted by stem cell scientists in Japan and the US, with the recent CE marking now enabling its use in Europe”.
Yokohama Japan – REPROCELL Inc. today announced that it has established the current good manufacturing practice (cGMP) cell processing suite at Life Innovation Center (LIC) in Tonomachi area in Kawasaki City for production of iPS Cell-derived Glial Progenitors (iGRP) for treatment of CNS disorders. The suite has been designed to support Clinical Trials of cell therapy products.
Wave 3 of the UK Government’s science and innovation audits (SIAs) have been published today, identifying a number of strengths in different industries across the country — including precision medicine innovation in Scotland, led by the University of Glasgow.
Glasgow UK, 12 March 2019 – REPROCELL Europe Ltd (REPROCELL), a UK-based human tissue research company, today announced a strategic partnership with Medicines Discovery Catapult.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).
© 2020 REPROCELL Inc. All rights reserved.
REPROCELL USA Inc. Registered office REPROCELL USA Inc., 9000 Virginia Manor Road, Suite 207, Beltsville, 20705, USA, Registered in United States